Foundation One is a genetic test capable of precisely identifying all cells and genes in the genetic profile of patients with solid tumors. Based on its results, physicians gain access to more accurate information, enabling them to adopt a personalized treatment approach for the patient.
Overview
Cancer cases worldwide are expected to increase by 77% by 2050
Patients with advanced or metastatic cancer, seeking targeted therapies.;
Patients with rare tumors, lacking standard treatment options.;
Patients who did not respond well to conventional treatments.
Genes Analyzed
Foundation One examines over 300 cancer-related genes, varying according to the test version (such as FoundationOne CDx, FoundationOne Liquid, etc.). Frequently analyzed genes include:
BRCA1/BRCA2 (related to breast and ovarian cancer).
TP53 (common in various cancer types).
EGFR, KRAS, ALK, BRAF (often associated with lung cancer and other types).